Royalty Pharma
ISIN GB00BMVP7Y09
|WKN A2P62D
Market cap (in EUR)
16,875.79 m
Country
United States
Sector
Healthcare
Dividend yield
2.55%
Overview
Description
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 16,875.79 m |
| EPS, EUR | 2.28 |
| P/B ratio | 2.12 |
| P/E ratio | 13.60 |
| Dividend yield | 2.55% |
Income statement (2024)
| Revenue, EUR | 2,092.62 m |
| Net income, EUR | 794.11 m |
| Profit margin | 37.95% |
What ETF is Royalty Pharma in?
There are 231 ETFs which contain Royalty Pharma. All of these ETFs are listed in the table below. The ETF with the largest weighting of Royalty Pharma is the L&G Pharma Breakthrough UCITS ETF.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
